{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T13:02:41Z","timestamp":1761224561816,"version":"build-2065373602"},"reference-count":6,"publisher":"Danish Medical Association","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dan Med J"],"abstract":"<jats:p>INTRODUCTION. Biologic therapies like infliximab and vedolizumab effectively treat inflammatory bowel disease (IBD), but post-infusion observation consumes considerable clinical resources. This study evaluated whether post-infusion observation periods may be safely reduced or eliminated.\n\nMETHODS. A retrospective analysis included all IBD patients receiving infliximab or vedolizumab from January 2019 to December 2020 at Sygehus Lillebaelt, Denmark. Data included infusion counts, observation duration, timing and severity of reactions.\n\nRESULTS. Among 380 patients receiving 3,847 infusions, 43 reactions (1.1%) occurred exclusively during infusions, mostly within the first 15 minutes. No reactions were reported after infusion had concluded.\n\nCONCLUSIONS. Routine post-infusion observation after infliximab and vedolizumab appears unnecessary. Reducing or eliminating this practice may optimise clinical resources without compromising patient safety.\n\nFUNDING. None.\n\nTRIAL REGISTRATION. Not relevant.<\/jats:p>","DOI":"10.61409\/a03250206","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T06:47:32Z","timestamp":1759906052000},"page":"1-7","source":"Crossref","is-referenced-by-count":0,"title":["No post-infusion reactions after infliximab or vedolizumab"],"prefix":"10.61409","author":[{"given":"Lars Koch","family":"Hansen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karina Winther","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara Emmerich","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael Dam","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"40208","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Dorn-Rasmussen M, Lo B, Zhao M, et al. The incidence and prevalence of paediatric- and adult-onset inflammatory bowel disease in Denmark during a 37-year period: a nationwide cohort study (1980-2017). J Crohns Colitis. 2023;17(2):259-268. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjac138","DOI":"10.1093\/ecco-jcc\/jjac138"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Wewer MD, Arp L, Sarikaya M, et al. The use and efficacy of biological therapies for inflammatory bowel disease in a Danish tertiary centre 2010-2020. Crohns Colitis 360. 2022;4(4):otac041. https:\/\/doi.org\/10.1093\/crocol\/otac041","DOI":"10.1093\/crocol\/otac041"},{"key":"ref2","unstructured":"RADS. Medication recommendation involving expensive drugs for the treatment of chronic inflammatory bowel diseases (IBD). RADS, 2017. https:\/\/rads.dk\/media\/4367\/lmr-gastro-31.pdf (Jul 2025)"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Younge L, Ibarra A, Healy C, et al. PWE-070 Post biological infusion monitoring; is it really necessary? Gut. 2018;67:A102. https:\/\/doi.org\/10.1136\/gutjnl-2018-BSGAbstracts.202","DOI":"10.1136\/gutjnl-2018-BSGAbstracts.202"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Younge L, Whitley L, Azana S, et al. N03 can post biologic infusion monitoring be reduced? A multi-centred retrospective study. J Crohns Colitis. 2019;13(suppl 1):S558. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjy222.991","DOI":"10.1093\/ecco-jcc\/jjy222.991"},{"key":"ref5","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v.5.0. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm (Jul 2025)"}],"container-title":["Danish Medical Journal"],"original-title":[],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:38:17Z","timestamp":1761223097000},"score":1,"resource":{"primary":{"URL":"https:\/\/ugeskriftet.dk\/dmj\/A03250206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":6,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.61409\/a03250206","relation":{},"ISSN":["2245-1919"],"issn-type":[{"type":"electronic","value":"2245-1919"}],"subject":[],"published":{"date-parts":[[2025]]}}}